Verastem (VSTM) Misses Q1 EPS by 5c, Revenues Miss; FY19 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NVDA
7. SPY
8. NRIX
9. SUNS
10. OIG

Go back to Verastem (VSTM) Misses Q1 EPS by 5c, Revenues Miss; FY19 Revenue Guidance Below Consensus

Verastem Oncology Reports First Quarter 2019 Financial Results

May 9, 2019 4:05 PM EDT

Company Reports $1.7 Million in Net Product Revenues from COPIKTRA; Issues Product Revenue Guidance for 2019

Cash, Cash Equivalents and Short-Term Investments of $211.7 Million as of March 31, 2019

Company to Host Conference Call Today at 4:30 PM ET

BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology, (or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three months ended March 31, 2019.

We are now into the... More